SPRY ARS Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1671858 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.5%
TTM net income YoY-149.7%
TTM EPS YoY-148.1%
Revenue 3-yr CAGR1,496.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-161.5%
Net margin-163.6%
FCF margin-149.9%
EBITDA margin-160.2%
Returns
ROE-294.6%
ROA-64.0%
ROIC (approx.)-116.0%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio3.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $37.71M | $33.66M | $22.68M | $28.09M | $32.50M | $15.72M | $7.97M | $86.58M |
| R&D expense | $18.26M | $4.70M | $4.34M | $3.44M | $2.75M | $4.04M | $2.95M | $3.03M |
| SG&A expense | $43.52M | $77.58M | $72.20M | $59.95M | $74.75M | $54.31M | $41.10M | $35.49M |
| Operating income | -$34.17M | -$61.47M | -$60.15M | -$41.47M | -$53.19M | -$47.61M | -$37.18M | $47.20M |
| Net income | -$35.59M | -$62.34M | -$60.62M | -$41.32M | -$51.15M | -$44.88M | -$33.94M | $49.93M |
| EBITDA | -$33.76M | -$61.05M | -$59.75M | -$41.05M | -$52.80M | -$47.34M | -$36.90M | $47.23M |
| EPS (basic) | -0.36 | -0.63 | -0.61 | — | -0.52 | -0.46 | -0.35 | — |
| EPS (diluted) | -0.36 | -0.63 | -0.61 | — | -0.52 | -0.46 | -0.35 | — |
| Weighted avg. shares (diluted) | 99.69M | 99.31M | 99.30M | — | 98.81M | 98.36M | 98.06M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $25.62M | $8.16M | $24.32M | $41.32M | $59.56M | $51.54M | $39.86M | $50.82M |
| Short-term investments | $112.73M | $135.68M | $176.65M | $203.67M | $228.65M | $188.59M | $235.86M | $263.20M |
| Receivables | $52.76M | $46.84M | $28.66M | $25.35M | $36.45M | $25.13M | $9.30M | $8.18M |
| Inventory | $33.43M | $30.73M | $32.04M | $31.42M | $21.43M | $22.11M | $7.27M | $10.52M |
| Current assets | $211.03M | $211.51M | $245.24M | $284.90M | $338.86M | $281.44M | $303.86M | $334.30M |
| PP&E, net | $1.93M | $2.08M | $2.29M | $2.46M | $1.21M | $1.07M | $1.07M | $1.07M |
| Intangibles | $13.62M | $13.90M | $14.18M | $14.45M | $14.73M | $12.97M | $7.24M | $7.37M |
| Total assets | $251.48M | $249.50M | $287.57M | $327.65M | $372.80M | $313.47M | $327.32M | $351.15M |
| Current liabilities | $64.90M | $60.86M | $49.61M | $39.15M | $50.88M | $45.60M | $27.62M | $23.44M |
| Long-term debt | $121.81M | $96.68M | $96.52M | $96.37M | $96.23M | — | — | $0 |
| Total debt | $121.81M | $96.68M | $96.52M | $96.37M | $96.23M | — | — | $0 |
| Total liabilities | $263.44M | $236.98M | $226.26M | $213.39M | $225.15M | $121.15M | $98.34M | $94.36M |
| Shareholders' equity | -$11.96M | $12.51M | $61.31M | $114.26M | $147.66M | $192.32M | $228.97M | $256.80M |
| Net debt | $96.19M | $88.51M | $72.20M | $55.06M | $36.67M | — | — | -$50.82M |
| Shares outstanding | 100.25M | 99.44M | 99.30M | 99.29M | 98.84M | 98.70M | 98.13M | 97.95M |
| Cash flow statement | ||||||||
| Operating cash flow | -$33.71M | -$60.93M | -$44.95M | -$43.48M | -$47.05M | -$39.59M | -$40.74M | $42.00M |
| Capital expenditure | $0 | $0 | $0 | $0 | $197,000 | $51,000 | $91,000 | $302,000 |
| Free cash flow | -$33.71M | -$60.93M | -$44.95M | -$43.48M | -$47.24M | -$39.64M | -$40.83M | $41.70M |
| Investing cash flow | $23.41M | $41.57M | $27.79M | $24.11M | -$44.98M | $48.57M | $29.06M | -$101.76M |
| Financing cash flow | $27.76M | $3.20M | $159,000 | $1.13M | $100.05M | $2.70M | $725,000 | $70.92M |
| Depreciation & amortization | $415,000 | $416,000 | $397,000 | $417,000 | $391,000 | $279,000 | $280,000 | $29,000 |
| Stock-based compensation | $8.12M | $12.39M | $7.42M | $5.74M | $5.69M | $5.37M | $5.30M | $4.26M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.